These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20381925)

  • 21. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs.
    Papich MG
    Vet Microbiol; 2014 Jul; 171(3-4):480-6. PubMed ID: 24513278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
    Li C; Du X; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2007 May; 51(5):1725-30. PubMed ID: 17307978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting antibiotics based on pharmacokinetic and pharmacodynamic principles.
    Klutman NE
    Pharm Pract Manag Q; 1996 Jul; 16(2):9-12. PubMed ID: 10161616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pharmacodynamic parameters for antimicrobial agents.
    Li RC
    Int J Antimicrob Agents; 2000 Feb; 13(4):229-35. PubMed ID: 10755236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetic and pharmacodynamic concepts for an interpretative reading of the antibiogram].
    Soriano F
    Enferm Infecc Microbiol Clin; 2002 Oct; 20(8):407-11; quiz 412. PubMed ID: 12372239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic/pharmacodynamic evaluation of antimicrobial treatments of orofacial odontogenic infections.
    Isla A; Canut A; Gascón AR; Labora A; Ardanza-Trevijano B; Solinís MA; Pedraz JL
    Clin Pharmacokinet; 2005; 44(3):305-16. PubMed ID: 15762771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
    Li RC; Zhu M; Schentag JJ
    Clin Pharmacokinet; 1999 Jul; 37(1):1-16. PubMed ID: 10451780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EUCAST expert rules in antimicrobial susceptibility testing.
    Leclercq R; Cantón R; Brown DF; Giske CG; Heisig P; MacGowan AP; Mouton JW; Nordmann P; Rodloff AC; Rossolini GM; Soussy CJ; Steinbakk M; Winstanley TG; Kahlmeter G
    Clin Microbiol Infect; 2013 Feb; 19(2):141-60. PubMed ID: 22117544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.
    Maglio D; Nicolau DP
    Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Rao GG; Landersdorfer CB
    Int J Antimicrob Agents; 2021 Aug; 58(2):106368. PubMed ID: 34058336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer.
    Theuretzbacher U
    Clin Infect Dis; 2012 Jun; 54(12):1785-92. PubMed ID: 22437238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Limitations of MIC as the sole criterion in antimicrobial drug dosage regimen design: the need for full characterization of antimicrobial pharmacodynamic profile especially for drug-resistant organisms.
    Gehring R; Riviere JE
    Vet J; 2013 Oct; 198(1):15-8. PubMed ID: 24025153
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
    Dudley MN; Ambrose PG
    Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of fluoroquinolone pharmacodynamics.
    Wright DH; Brown GH; Peterson ML; Rotschafer JC
    J Antimicrob Chemother; 2000 Nov; 46(5):669-83. PubMed ID: 11062185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.
    Sánchez-Navarro A; Sánchez Recio MM
    Clin Pharmacokinet; 1999 Oct; 37(4):289-304. PubMed ID: 10554046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.
    Dalhoff A; Ambrose PG; Mouton JW
    Infection; 2009 Aug; 37(4):296-305. PubMed ID: 19629383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Monte Carlo analysis of peritoneal antimicrobial pharmacokinetics.
    Hota S; Crooke P; Hotchkiss J
    Adv Exp Med Biol; 2011; 696():401-10. PubMed ID: 21431580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breakpoints: current practice and future perspectives.
    Mouton JW
    Int J Antimicrob Agents; 2002 Apr; 19(4):323-31. PubMed ID: 11978503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.